We chatted to IronRidge Resources' CEO Vincent Mascolo who explains why the company has become a lithium explorer. Watch the video here.
(ShareCast News) - Hikma Pharmaceuticals's chief Said Darwazah boosted his stake in the generic drugs firm on Wednesday to 5.49% through the acquisition of 30,000 shares at an individual price of 2,271p. The transaction was carried out by Vidacos Nominees on behalf of Darhold Limited, in which Darwa
(ShareCast News) - Hikma Pharmaceuticals' newest board member has bought himself some skin in the game, following his chief executive's lead. US public affairs veteran John Castellani, who was appointed to the board in February, spent around £53,000 buying 2,500 shares at a price of 2,103p apiece.
(ShareCast News) - Hikma Pharmaceuticals said on Friday that its abbreviated new drug application for fluticasone propionate and salmeterol inhalation powder has been accepted for filing by the Food and Drug Administration in the US. The product is the generic version of GlaxoSmithKline's Advair Dis
(ShareCast News) - Shares in pharmaceuticals companies Shire, AstraZeneca and GlaxoSmithKline rallied on Wednesday as investors bet that the termination of Pfizer's agreement to buy Allergan might make the London-listed companies bid targets. US drug maker Pfizer said on Wednesday that its $160bn ag
(ShareCast News) - The chairman and chief executive of Hikma Pharmaceuticals has purchased more than £600,000 worth of shares in the drugmaker. Said Darwazah bought 30,000 shares for 2,055.00p each, totalling £616,499.98 JP Morgan on Wednesday reiterated its 'overweight' rating on the stock and set